Gaurav Bhandari
Managing Partner at Long Arc Capital
New York, New York
Gaurav Bhandari, Managing Partner at Long Arc Capital is an active investor based in New York, New York. This profile covers what Gaurav Bhandari backs, at which stage, and how founders can reach out in 2026.
- Investor type
- VC
- Stages
- SeedSeries A
- Invests in
- SaaS & Enterprise
- Location
- New York, New York
- Typical check
- $625K
How to reach Gaurav Bhandari
Angels and operators like Gaurav Bhandari reply to specific, personalized notes that show real traction, not mass blasts. Build a verified list, write a note that fits their thesis, and track replies, all on Round Funded.
Connect with Gaurav Bhandari
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise.
Frequently Asked Questions
What does Gaurav Bhandari invest in?
Gaurav Bhandari invests in SaaS & Enterprise, typically at Seed and Series A. Match your sector and stage, then reach out with a personalized pitch.
What stage does Gaurav Bhandari invest at?
Gaurav Bhandari typically invests at Seed and Series A. Lead with traction that fits the stage when you reach out.
What is Gaurav Bhandari's typical check size?
Gaurav Bhandari typically writes checks around $625K. Use it as a signal for whether your raise fits their stage.
How do I contact Gaurav Bhandari?
Unlock Gaurav Bhandari's verified email on Round Funded and send a personalized pitch. We surface only deliverable contacts so your outreach lands.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.